Let’s work together against superbugs

Pharma industry calls on governments to help tackle antibiotic resistance

Like Comment

More than 80 drug, diagnostics and biotechnology companies have come together to ask governments to move forward, in collaboration with companies, to support investment in the development of antibiotics, diagnostics, vaccines, and other products needed to prevent and treat drug-resistant infections. This is in their opinion necessary to generate dependable and sustainable markets for antibiotics, to allow companies to make the necessary investment in R&D for new antibiotic discovery and development. STAT has a nice news story on this.

In particular, they ask for improved efforts to conserve antibiotics, improve how antibiotics are prescribed, and change health systems that directly reward doctors, pharmacists and veterinarians for prescribing antibiotics in great volumes. To this effect, the U.S. Centers for Disease Control and Prevention (CDC), in cooperation with the American College of Physicians (ACP), has issued new guidelines to prevent doctors from over-prescribing antibiotics, as new research indicates that up to 50 percent of antibiotic prescriptions given out by doctors in an outpatient setting may be inappropriate or even unnecessary.

Nonia Pariente

Chief Editor, Nature Microbiology

I come from a mid-sized city on the northwestern coast of Spain. My interest in science initially took me to Madrid, where I finished university and received a PhD in molecular biology. In Madrid, I studied RNA virus evolution and new antiviral strategies with Esteban Domingo. I then moved to UCLA, where I focused on developing lentiviral vectors for gene therapy in Irvin Chen’s laboratory. In 2007, I made the plunge from bench to desk and joined the EMBO Reports editorial team as Reviews Editor, becoming Scientific Editor two years later and Senior Editor in 2012. At EMBO Reports, I was responsible for microbiology and immunology, among other areas, and spent many years expanding my understanding and love for all things microbial. In the summer of 2015, I joined the Nature Microbiology editorial launch team, handling all things related to virology and mycology (and for a brief while parasitology) and -after a couple of stints covering microbiology at Nature- I became the Chief Editor of Nature Microbiology in 2019. I look forward to interacting with the community and providing a venue to publish the most important advances in the field.